Literature DB >> 28497423

Validation of the prognostic value of new sub-stages within the AJCC 8th edition of non-small cell lung cancer.

O Abdel-Rahman1.   

Abstract

BACKGROUND: The 8th edition of the American Joint Committee on Cancer (AJCC) staging system for non-small cell lung cancer (NSCLC) has been released. The current study tried to validate the prognostic significance of the new system among patients registered within the surveillance, epidemiology and end results (SEER) database.
METHODS: SEER database (2010-2013) has been accessed through SEER*Stat program and AJCC 8th edition stages were reconstructed utilizing the collaborative stage descriptions. Overall and lung cancer-specific survival analyses according to both 7th and 8th editions were conducted through Kaplan-Meier analysis and multivariate analysis was conducted through a Cox proportional hazard model.
RESULTS: A total of 127,096 patients with NSCLC were identified in the period from 2010 to 2013. For overall survival assessment according to the 8th edition, P values for all pair-wise comparisons among different stages were significant (<0.0001) except for the comparisons between stage IB and IIA (P = 0.146); stage IIA and IIB (P = 0.165). For lung cancer-specific survival according to the 8th edition, P values for all pair-wise comparisons among different stages were significant (<0.001). Among patients with stage I disease, multivariate analysis for factors affecting overall and lung cancer-specific survival among patients with stage I disease was conducted. The following factors were associated with worse overall and lung cancer-specific survival: age ≥70 years, more advanced stage, male gender, squamous histology, no surgery and no radiotherapy (P < 0.0001 for all factors).
CONCLUSION: This SEER analysis supports the prognostic significance of the added sub-stages described within AJCC 8th edition stages I and III. Further work is needed to incorporate molecular markers and personalize the future editions of the AJCC staging system.

Entities:  

Keywords:  AJCC; Lung cancer; NSCLC; SEER

Mesh:

Year:  2017        PMID: 28497423     DOI: 10.1007/s12094-017-1673-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  13 in total

1.  Validation of the proposed International Association for the Study of Lung Cancer non-small cell lung cancer staging system revisions for advanced bronchioloalveolar carcinoma using data from the California Cancer Registry.

Authors:  Jason A Zell; S-H Ignatius Ou; Argyrios Ziogas; Hoda Anton-Culver
Journal:  J Thorac Oncol       Date:  2007-12       Impact factor: 15.609

2.  Targeted therapy for lung cancer: present and future.

Authors:  Charu Aggarwal
Journal:  Ann Palliat Med       Date:  2014-07

3.  Causes of death in long-term lung cancer survivors: a SEER database analysis.

Authors:  Omar Abdel-Rahman
Journal:  Curr Med Res Opin       Date:  2017-05-20       Impact factor: 2.580

4.  Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry.

Authors:  Jianjun Zhang; Kathryn A Gold; Heather Y Lin; Stephen G Swisher; Yan Xing; J Jack Lee; Edward S Kim; William N William
Journal:  J Thorac Oncol       Date:  2015-04       Impact factor: 15.609

5.  Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis.

Authors:  Omar Abdel-Rahman; Hesham Elhalawani
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

6.  Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003.

Authors:  Daniel Morgensztern; Saiama Waqar; Janakiraman Subramanian; Feng Gao; Kathryn Trinkaus; Ramaswamy Govindan
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

7.  Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California Cancer Registry.

Authors:  Sai-Hong Ignatius Ou; Jason A Zell
Journal:  J Thorac Oncol       Date:  2008-03       Impact factor: 15.609

8.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

Authors:  Peter Goldstraw; Kari Chansky; John Crowley; Ramon Rami-Porta; Hisao Asamura; Wilfried E E Eberhardt; Andrew G Nicholson; Patti Groome; Alan Mitchell; Vanessa Bolejack
Journal:  J Thorac Oncol       Date:  2016-01       Impact factor: 15.609

Review 9.  Targeted therapy for localized non-small-cell lung cancer: a review.

Authors:  Nicolas Paleiron; Olivier Bylicki; Michel André; Emilie Rivière; Frederic Grassin; Gilles Robinet; Christos Chouaïd
Journal:  Onco Targets Ther       Date:  2016-07-05       Impact factor: 4.147

10.  Prognostic effect of liver metastasis in lung cancer patients with distant metastasis.

Authors:  Yijiu Ren; Chenyang Dai; Hui Zheng; Fangyu Zhou; Yunlang She; Gening Jiang; Ke Fei; Ping Yang; Dong Xie; Chang Chen
Journal:  Oncotarget       Date:  2016-08-16
View more
  9 in total

1.  Validation of the AJCC 8th lung cancer staging system among patients with small cell lung cancer.

Authors:  O Abdel-Rahman
Journal:  Clin Transl Oncol       Date:  2017-08-14       Impact factor: 3.405

2.  Chemotherapy and Radiation Versus Chemotherapy Alone for Elderly Patients With N3 Stage IIIB NSCLC.

Authors:  Angel Qin; Elizabeth Lusk; Stephanie Daignault-Newton; Bryan J Schneider
Journal:  Clin Lung Cancer       Date:  2019-04-19       Impact factor: 4.785

3.  Modified staging system for pulmonary carcinoids on the basis of lung cancer TNM system.

Authors:  O Abdel-Rahman
Journal:  Clin Transl Oncol       Date:  2017-10-11       Impact factor: 3.405

4.  Clinical associations and prognostic value of site-specific metastases in non-small cell lung cancer: A population-based study.

Authors:  Zihan Xu; Qiao Yang; Xiewan Chen; Linpeng Zheng; Luping Zhang; Yongxin Yu; Mingjing Chen; Qiai You; Jianguo Sun
Journal:  Oncol Lett       Date:  2019-04-05       Impact factor: 2.967

5.  Prognostic value of insulin-like growth factor 2 mRNA-binding protein 3 and vascular endothelial growth factor-A in patients with primary non-small-cell lung cancer.

Authors:  Jiannan Liu; Ying Liu; Wenjing Gong; Xiangshuo Kong; Congcong Wang; Shuhua Wang; Aina Liu
Journal:  Oncol Lett       Date:  2019-09-10       Impact factor: 2.967

6.  A Prediction Rule for Overall Survival in Non-Small-Cell Lung Cancer Patients with a Pathological Tumor Size Less Than 30 mm.

Authors:  Wang-Yu Zhu; Ke-Xin Fang; Jian-Ying He; Ri Cui; Yong-Kui Zhang; Han-Bo Le
Journal:  Dis Markers       Date:  2019-05-02       Impact factor: 3.434

7.  Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.

Authors:  Dan Yan; Yi Chen
Journal:  Sci Rep       Date:  2021-04-27       Impact factor: 4.379

8.  Prognostic Impact of Single and Multiple Descriptors in Pathologically Staged T3N0M0 NSCLC.

Authors:  Takefumi Komiya; Emily Powell; Shinkichi Takamori
Journal:  JTO Clin Res Rep       Date:  2020-10-20

9.  Verification of the eighth edition of the UICC-TNM classification on surgically resected lung adenocarcinoma: Comparison with previous classification in a local center.

Authors:  Hiroshi Minato; Kazuyoshi Katayanagi; Hiroshi Kurumaya; Nobuhiro Tanaka; Hideki Fujimori; Yoshio Tsunezuka; Takeshi Kobayashi
Journal:  Cancer Rep (Hoboken)       Date:  2021-06-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.